Fulcrum Therapeutics基本情况
情况介绍
Fulcrum Therapeutics, Inc. (FULC) is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for genetically defined diseases. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts. FULC's lead product candidate, losmapimod, is currently in clinical trials for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
股本股东分析
As of the latest report, Fulcrum Therapeutics has a total of 54.4 million shares outstanding. The major institutional shareholders include FMR LLC (14.5%), RTW Investments LP (11.6%), and RA Capital Management LP (10.3%). The company's insider ownership stands at approximately 4.2%. The stock has experienced significant volatility, with a 52-week range between $2.25 and $15.00.
经营能力分析
FULC's operating expenses for the last fiscal year totaled $123.5 million, primarily driven by research and development costs of $98.7 million. The company reported a net loss of $118.4 million. Despite the high R&D expenditure, Fulcrum maintains a strong cash position with $215.6 million in cash and cash equivalents, providing a runway to continue its clinical trials.
| Metric | Value |
|---|---|
| Operating Expenses | $123.5 million |
| R&D Expenses | $98.7 million |
| Net Loss | $118.4 million |
| Cash & Equivalents | $215.6 million |
竞争能力分析
Fulcrum operates in the competitive field of genetic medicine, with key competitors including Sarepta Therapeutics, PTC Therapeutics, and Biogen. FULC's focus on small molecule therapies for rare diseases gives it a niche advantage, but the company must continue to advance its clinical trials to maintain its competitive edge. The success of losmapimod in treating FSHD will be crucial for its market position.
发展情景分析
FULC is poised for growth if its lead candidate, losmapimod, successfully completes clinical trials and gains regulatory approval. The company's pipeline also includes FTX-6058 for sickle cell disease, which is in early-stage development. The potential market for FSHD treatment is estimated at $1.5 billion annually, providing significant upside potential.
重大事项
- In Q2 2023, Fulcrum announced positive preliminary data from the Phase 2b REACH trial of losmapimod in FSHD.
- The company received a $10 million milestone payment from MyoKardia in 2022 for the advancement of FTX-6058.
- Fulcrum raised $80 million through a public offering in 2022 to fund its clinical programs.
公司基本情况小结
Fulcrum Therapeutics presents a high-risk, high-reward investment opportunity. The company's strong cash position and focus on niche genetic diseases provide a solid foundation for growth. However, the significant net losses and ongoing clinical trial risks pose challenges. The success of losmapimod in the FSHD market will be pivotal for FULC's investment value. Investors should monitor clinical trial progress and regulatory updates closely.
- 最新
- 最热
只看作者